» Articles » PMID: 1941081

Identification and Localization of Muscarinic Acetylcholine Receptor Proteins in Brain with Subtype-specific Antibodies

Overview
Journal J Neurosci
Specialty Neurology
Date 1991 Oct 1
PMID 1941081
Citations 280
Authors
Affiliations
Soon will be listed here.
Abstract

mRNAs encoding five genetically distinct muscarinic ACh receptors are present in the CNS. Because of their pharmacological similarities, it has not been possible to detect the individual encoded proteins; thus, their physiological functions are not well defined. To characterize the family of proteins, a panel of subtype-selective antibodies was generated against recombinant muscarinic receptor proteins and shown to bind specifically to each of the cloned receptors. Using immunoprecipitation, three receptor proteins (m1, m2, and m4) accounted for the vast majority of the total solubilized muscarinic binding sites in rat brain. These receptor subtypes had marked differences in regional and cellular localization as shown by immunocytochemistry. The m1-protein was present in cortex and striatum and was localized to cell bodies and neurites, consistent with its role as a major postsynaptic muscarinic receptor. The m2-receptor protein was abundant in basal forebrain, scattered striatal neurons, mesopontine tegmentum, and cranial motor nuclei; this distribution is similar to that of cholinergic neurons and suggests that m2 is an autoreceptor. However, m2 was also present in noncholinergic cortical and subcortical structures, providing evidence that this subtype may presynaptically modulate release of other neurotransmitters and/or function postsynaptically. The m4-receptor was enriched in neostriatum, olfactory tubercle, and islands of Calleja, indicating an important role in extrapyramidal function. These results clarify the roles of these genetically defined receptor proteins in cholinergic transmission in brain.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

A sex-specific effect of M muscarinic cholinergic autoreceptor deletion on locomotor stimulation by cocaine and scopolamine.

Berezovskaia A, Thomsen M, Fink-Jensen A, Wortwein G Front Mol Neurosci. 2024; 17:1451010.

PMID: 39737113 PMC: 11683150. DOI: 10.3389/fnmol.2024.1451010.


Reduced striatal M4-cholinergic signaling following dopamine loss contributes to parkinsonian and l-DOPA-induced dyskinetic behaviors.

Nielsen B, Ford C Sci Adv. 2024; 10(47):eadp6301.

PMID: 39565858 PMC: 11578179. DOI: 10.1126/sciadv.adp6301.


Differential cholinergic innervation of lemniscal versus non-lemniscal regions of the inferior colliculus.

Noftz W, Echols E, Beebe N, Mellott J, Schofield B J Chem Neuroanat. 2024; 139:102443.

PMID: 38914378 PMC: 11827475. DOI: 10.1016/j.jchemneu.2024.102443.


Current Findings and Potential Mechanisms of KarXT (Xanomeline-Trospium) in Schizophrenia Treatment.

Azargoonjahromi A Clin Drug Investig. 2024; 44(7):471-493.

PMID: 38904739 DOI: 10.1007/s40261-024-01377-9.


Multiple cholinergic receptor subtypes coordinate dual modulation of acetylcholine on anterior and posterior paraventricular thalamic neurons.

Ye Q, Nunez J, Zhang X J Neurochem. 2024; 168(6):995-1018.

PMID: 38664195 PMC: 11136594. DOI: 10.1111/jnc.16115.